Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
TCRX
#3152
TScan Therapeutics, Inc. Common Stock
1.0
6
-3.64%
Secteur:
Base:
Devise de Profit:
Range quotidien
Range Annuel
Changement quotidien
-3.64%
Changement Mensuel
-4.50%
Evolution sur 6 mois
-43.32%
Changement Annuel
-48.29%
Clôture Précédente
1.1
0
Open
1.0
6
Bid
Ask
Low
1.0
6
High
1.0
6
Volume
6
Marchés
Actions des Marchés US
Soins de Santé
TCRX
Open full chart
Financials
Overview
Relevé
Statistics
Dividends
Quarterly
Annual
Value
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
18.76 M
19.08 M
43.61 M
52.31 M
—
Valuation ratios
Enterprise value
-53.51 M
-4.54 M
662.44 M
324.42 M
602.51 M
Price to earnings ratio
—
-0.62
-4.2
-2.67
-6.93
Price to sales ratio
—
3.04
17.8
120.9
212.92
Price to cash flow ratio
—
0.62
6.1
3.07
7.61
Price to book ratio
—
0.41
2.48
1.41
2.08
Enterprise value to EBITDA ratio
—
—
—
—
—
Profitability ratios
Return on assets %
0.26
0.33
0.33
0.34
0.46
Return on equity %
0.3
0.67
0.59
0.53
0.77
Return on invested capital %
687.92
585.8
537.56
686.88
—
Gross margin %
100
100
100
100
400
Operating margin %
479.65
492.32
444
4 787.68
9 922.53
EBITDA margin %
—
—
—
—
—
Net margin %
479.49
489.26
423.86
4 527.66
9 580.2
Liquidity ratios
Quick ratio
—
—
—
—
—
Current ratio
7.76
7.17
6.51
8.14
30.19
Inventory turnover
—
—
—
—
—
Asset turnover
0.05
0.07
0.09
0.01
0.03
Solvency ratios
Debt to assets ratio
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
Long term debt to total assets ratio
—
0.15
0.1
0.09
0.41
Long term debt to total equity ratio
—
0.29
0.18
0.13
0.69
Per share metrics
Operating cash flow per share
—
2.77
0.94
0.99
1.04
EBIT per share
—
—
—
—
—
EBITDA per share
—
—
—
—
—
Total debt per share
—
—
—
—
—
Cash per share
—
4.99
2.93
2.59
7.63
Net current asset value per share
—
5.16
2.96
2.61
7.73
Tangible book value per share
—
4.13
2.3
2.15
6.24
Working capital per share
—
4.44
2.51
2.29
6.72
Book value per share
—
4.13
2.3
2.15
6.24
Nouvelles
TScan completes enrollment in trial cohort, receives FDA clearance
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates
Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains?
Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates
Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)
Tscan Therapeutics conserve sa note Neutre chez BTIG après l’événement ASH
Tscan Therapeutics stock holds Neutral rating at BTIG after ASH event
TScan to host KOL event discussing updated ALLOHA trial data
Morgan Stanley dégrade l’action Tscan Therapeutics suite aux essais retardés
Morgan Stanley downgrades Tscan Therapeutics stock on delayed trials
Le BPA de Tscan Therapeutics a dépassé les attentes de 0,06$, le CA a surpassé les prévisions